A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)
Conditions: Plaque Psoriasis Interventions: Drug: Deucravacitinib Sponsors: Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Pilot Study to Investigate Dietary Changes During Pregnancy
Conditions: Pregnancy Related Sponsors: German Institute of Human Nutrition Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa
Conditions: Fabry Disease Interventions: Drug: Pegunigalsidase-alfa Sponsors: Westf älische Wilhelms-Universität Münster; Chiesi GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Conditions: Triple Negative Breast Cancer Interventions: Drug: Sacituzumab govitecan; Drug: Pembrolizumab Sponsors: West German Study Group; Gilead Sciences; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
COMPASS: deCOMPressing stomA and two-Stage elective resection vs. emergency reSection in patients with left-sided obstructive colon cancer
DiscussionThe findings derived from this trial possess the potential to reshape the current clinical approach of emergency resection for obstructive left-sided colon cancer by favoring the bridge-to-surgery practice, provided that a reduction in morbidity can be achieved without compromising the oncological long-term outcome.Trial registrationGerman Clinical Trials Register (DRKS) under the identifier DRKS00031827. Registered on May 15, 2023.Protocol: 28.04.2023, protocol version 2.0F. (Source: Trials)
Source: Trials - October 5, 2023 Category: Research Source Type: clinical trials
BE Smart - Bariatric Patient - Empowerment in the Preparation and Follow-up of Bariatric Surgery Using the Smartvisit App (BESmart)
Conditions: Obesity; Bariatric Surgery Candidate Interventions: Device: smart visit app Sponsors: Wuerzburg University Hospital; aycan Medical Systems LTD, Innere Aumuehlstr. 5, 97076 Wuerzburg , Germany Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Interventions: Drug: Imatinib; Drug: Ponatinib; Drug: Blinatumomab; Other: Indication for stem cell transplantation Sponsors: Goethe University; Deutsche Leuk ämie-& Lymphom-Hilfe; German Federal Ministry of Education and Research Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Initiative for Clinical Long-read Sequencing
Conditions: Genetic Predisposition Interventions: Genetic: Next-Generation Sequencing (NGS) Sponsors: University Hospital Tuebingen; RWTH Aachen University; Medical University of Hannover; Charite University, Berlin, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Prospective, Randomized Controlled Trial to Investigate the Impact of AI on Shared Decision Making in Post-kidney Transplant Care
Condition: Kidney Transplant Failure Intervention: Other: AI-based risk prediction for kidney graft loss Sponsor: Charite University, Berlin, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Condition: Head and Neck Cancer Interventions: Drug: Xevinapant; Drug: Cisplatin; Radiation: intensity-modulated radiation therapy (IMRT) Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Conditions: Head and Neck Cancer Interventions: Drug: Xevinapant; Drug: Cisplatin; Radiation: intensity-modulated radiation therapy (IMRT) Sponsors: EMD Serono Research& Development Institute, Inc.; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Prospective, Randomized Controlled Trial to Investigate the Impact of AI on Shared Decision Making in Post-kidney Transplant Care
Conditions: Kidney Transplant Failure Interventions: Other: AI-based risk prediction for kidney graft loss Sponsors: Charite University, Berlin, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
Conditions: Type2diabetes; PreDiabetes; Renal Failure Interventions: Drug: Dapagliflozin (Forxiga ®); Drug: Placebo matching Dapaglifolzin; Behavioral: Lifestyle Intervention Sponsors: University Hospital Tuebingen; German Federal Ministry of Education and Research; German Center for Diabetes Research; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A randomised controlled trial in preterm infants comparing prophylactic with selective “less invasive surfactant administration” (pro.LISA)
DiscussionRobust data concerning the possible long-term benefits of prophylactic LISA treatment are lacking. The current observational data from the German Neonatal Network indicate that approximately 50% of preterm infants with supplemental oxygen at or below 30% within the first hour of life are treated with LISA. The pro.LISA trial will provide short- and long-term outcomes of preterm infants receiving prophylactic treatment and will clarify if prophylactic treatment should be given to all preterm infants or if the current practice of selective treatment if supplemental oxygen exceeds 30% is more appropriate.Trial regis...
Source: Trials - September 26, 2023 Category: Research Source Type: clinical trials
Register Schweres Asthma - German Asthma Net e.V.
Condition: Severe Asthma Intervention: Sponsors: German Asthma Net e.V.; AstraZeneca; GlaxoSmithKline; Sanofi; Chiesi Farmaceutici S.p.A. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
